Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.89% | 14.65% | 13.24% | 27.99% | 29.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.89% | 14.65% | 13.24% | 27.99% | 29.24% |
| Cost of Revenue | 13.44% | 27.77% | 2.71% | -0.81% | 18.81% |
| Gross Profit | 37.29% | -63.20% | 40.59% | 36.75% | 10.61% |
| SG&A Expenses | 7.39% | 7.80% | 7.50% | 12.33% | 6.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.71% | 21.86% | 4.18% | 2.94% | 15.04% |
| Operating Income | 7.38% | -29.47% | 7.28% | 13.55% | -0.21% |
| Income Before Tax | 3.86% | -34.78% | 12.80% | 12.02% | -4.67% |
| Income Tax Expenses | 126.56% | 188.12% | 10.37% | 187.91% | 110.37% |
| Earnings from Continuing Operations | 3.49% | -35.12% | 12.65% | 11.49% | -8.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.49% | -35.12% | 12.65% | 11.49% | -8.13% |
| EBIT | 7.38% | -29.47% | 7.28% | 13.55% | -0.21% |
| EBITDA | 7.33% | -31.69% | 7.66% | 14.41% | 0.93% |
| EPS Basic | 7.56% | -29.33% | 23.19% | 22.52% | 8.33% |
| Normalized Basic EPS | 8.00% | -28.83% | 20.92% | 24.73% | 12.84% |
| EPS Diluted | 7.56% | -29.33% | 23.19% | 22.52% | 8.33% |
| Normalized Diluted EPS | 8.00% | -28.83% | 20.92% | 24.73% | 12.84% |
| Average Basic Shares Outstanding | 4.41% | 4.48% | 13.72% | 14.24% | 17.95% |
| Average Diluted Shares Outstanding | 4.41% | 4.48% | 13.72% | 14.24% | 17.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |